DPP-4 inhibitors have no mortality benefit in type 2 diabetes, analysis shows
Research has shown that for patients with type 2 diabetes, SGLT-2 inhibitors and GLP-1 agonists were significantly associated with lower rates of death from all causes, compared with both controls and DPP-4 inhibitors.
Dipeptidyl peptidase-4 (DPP-4) inhibitors do not lower death rates in patients with type 2 diabetes, an analysis comparing them with other common treatments has shown.
Researchers carried out a network meta-analysis of 236 trials, including 176,310 participants who were treated with DPP-4 inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
The results, published in JAMA (17 April 2018), showed that SGLT-2 inhibitors and GLP-1 agonists were significantly associated with lower all-cause death rates compared with controls (hazard ratio [HR]: 0.80 and 0.88, respectively) and DPP-4 inhibitors (HR: 0.78 and 0.86, respectively). DPP-4 inhibitors were not associated with lower death rates than controls (HR: 1.02).
Incretin-based therapies have been shown in previous studies to improve glycaemic control in people with type 2 diabetes, but the authors of this analysis concluded: “Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.”
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204905
Recommended from Pharmaceutical Press
All you need to know about prescribing or administering drugs via enteral feeding tubes. Over 400 drug monographs as well as facts to inform clinical decision making.£54.00Buy now
Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.£82.00Buy now